Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody

The Prostate ◽  
2014 ◽  
Vol 74 (7) ◽  
pp. 743-755 ◽  
Author(s):  
Stefan Wiehr ◽  
Patrick Bühler ◽  
Dorothee Gierschner ◽  
Philipp Wolf ◽  
Anna-Maria Rolle ◽  
...  
2020 ◽  
Vol 44 (2) ◽  
pp. 116
Author(s):  
A. Bouleau ◽  
H. Nozach ◽  
M. Richard ◽  
S. Dubois ◽  
B. Kuhnast ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Sara S. Rinne ◽  
Charles Dahlsson Leitao ◽  
Joshua Gentry ◽  
Bogdan Mitran ◽  
Ayman Abouzayed ◽  
...  

AbstractUpregulation of the human epidermal growth factor receptor type 3 (HER3) is a common mechanism to bypass HER-targeted cancer therapy. Affibody-based molecular imaging has the potential for detecting and monitoring HER3 expression during treatment. In this study, we compared the imaging properties of newly generated 68Ga-labeled anti-HER3 affibody molecules (HE)3-ZHER3-DOTA and (HE)3-ZHER3-DOTAGA with previously reported [68Ga]Ga-(HE)3-ZHER3-NODAGA. We hypothesized that increasing the negative charge of the gallium-68/chelator complex would reduce hepatic uptake, which could lead to improved contrast of anti-HER3 affibody-based PET-imaging of HER3 expression. (HE)3-ZHER3-X (X = DOTA, DOTAGA) were produced and labeled with gallium-68. Binding of the new conjugates was specific in HER3 expressing BxPC-3 and DU145 human cancer cells. Biodistribution and in vivo specificity was studied in BxPC-3 xenograft bearing Balb/c nu/nu mice 3 h pi. DOTA- and DOTAGA-containing conjugates had significantly higher concentration in blood than [68Ga]Ga-(HE)3-ZHER3-NODAGA. Presence of the negatively charged 68Ga-DOTAGA complex reduced the unspecific hepatic uptake, but did not improve overall biodistribution of the conjugate. [68Ga]Ga-(HE)3-ZHER3-DOTAGA and [68Ga]Ga-(HE)3-ZHER3-NODAGA had similar tumor-to-liver ratios, but [68Ga]Ga-(HE)3-ZHER3-NODAGA had the highest tumor uptake and tumor-to-blood ratio among the tested conjugates. In conclusion, [68Ga]Ga-(HE)3-ZHER3-NODAGA remains the favorable variant for PET imaging of HER3 expression.


1999 ◽  
Vol 26 (2) ◽  
pp. 249-258 ◽  
Author(s):  
Anna Lövqvist ◽  
Hans Lundqvist ◽  
Mark Lubberink ◽  
Vladimir Tolmachev ◽  
Jörgen Carlsson ◽  
...  

2014 ◽  
Vol 25 (2) ◽  
pp. 335-341 ◽  
Author(s):  
S. Lütje ◽  
G. M. Franssen ◽  
R. M. Sharkey ◽  
P. Laverman ◽  
E. A. Rossi ◽  
...  

2014 ◽  
Vol 111 (3) ◽  
pp. 1108-1113 ◽  
Author(s):  
R. Tavare ◽  
M. N. McCracken ◽  
K. A. Zettlitz ◽  
S. M. Knowles ◽  
F. B. Salazar ◽  
...  

2009 ◽  
Vol 50 (9) ◽  
pp. 1500-1508 ◽  
Author(s):  
T. Olafsen ◽  
D. Betting ◽  
V. E. Kenanova ◽  
F. B. Salazar ◽  
P. Clarke ◽  
...  

2015 ◽  
Vol 103 (6) ◽  
Author(s):  
Sebastian Kuhn ◽  
Ingo Spahn ◽  
Bernhard Scholten ◽  
Heinz H. Coenen

AbstractTo evaluate the PET-imaging properties of the promising positron emitter


2008 ◽  
Vol 49 (11) ◽  
pp. 1828-1835 ◽  
Author(s):  
L. H. Wei ◽  
T. Olafsen ◽  
C. Radu ◽  
I. J. Hildebrandt ◽  
M. R. McCoy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document